Britain and America have secured a key bilateral deal that will guarantee no duties on UK medicine exports entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these key products will be held at nothing for a duration of three years.
This deal is in response to recent statements to significantly raise tariffs on branded drug imports, with figures mentioned as high as one hundred percent.
"This arrangement between the United Kingdom reinforces the worldwide climate for new treatments and brings long-overdue fairness to transatlantic drug exports," an announcement noted.
Trade Significance
Medicines are one of the the United Kingdom's biggest goods shipped to the US, which is clearly the biggest buyer for large British pharmaceutical firms.
Statistics indicate that in the year leading up to the third quarter, the UK exported drugs totaling over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that period.
"This agreement secures jobs, boosts capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," a minister stated.
Specific UK Commitments
The deal involves several key commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds topped 20%.
Industry Background
The deal takes place against a protracted row between the sector and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American patients were paying a premium for the same drugs than people in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been halted or abandoned, while major investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the last ten years.
